教員別検索 - 安室　秀樹

資格・免許

所属学会等

学術雑誌掲載論文

学会発表

（最終更新日：2025-04-25 05:05:06.367572）

  アムロ　ヒデキ   AMURO HIDEKI
  安室　秀樹
   所属   内科学第一講座

職種講師

■ 資格・免許

医師

■ 所属学会等

1.	2001/04～	日本内科学会
	2007	∟ 内科認定医
2.	2005/04～	日本リウマチ学会
	2010	∟ 日本リウマチ学会リウマチ専門医
3.	2006	日本免疫学会
4.	2007/07～	日本血液学会
5.	2008	日本臨床免疫学会
6.	2008/06～	日本呼吸器学会
7.	2010/08	日本臨床リウマチ学会
5件表示
全件表示(9件)

■ 学術雑誌掲載論文

1.	原著(症例報告除く)	Real-world comparative study of the efficacy of Janus kinase inhibitors in patients with rheumatoid arthritis: the ANSWER cohort study 2024/11
2.	原著(症例報告除く)	IL-6 inhibitors and JAK inhibitors as favourable treatment options for patients with anaemia and rheumatoid arthritis: ANSWER cohort study 2024/02
3.	原著(症例報告除く)	Drug retention of biologics and Janus kinase inhibitors in patients with rheumatoid arthritis: the ANSWER cohort study 2023/08
4.	原著(症例報告除く)	Prognostic factors affecting respiratory-related death in patients with rheumatoid arthritis complicated by interstitial lung disease: An ANSWER cohort study 2023/08
5.	原著(症例報告除く)	Add-on Effectiveness of Methotrexate or Iguratimod in Patients with Rheumatoid Arthritis Exhibiting an Inadequate Response to Janus Kinase Inhibitors: The ANSWER Cohort Study 2023/07
6.	原著(症例報告除く)	Prognostic Factors Affecting Death in Patients with Rheumatoid Arthritis Complicated by Pneumocystis jirovecii Pneumonia and One-Year Clinical Course: The ANSWER Cohort Study 2023/04
7.	原著(症例報告除く)	Favorable clinical response and drug retention of anti-IL-6 receptor inhibitor in rheumatoid arthritis with high CRP levels: the ANSWER cohort study 2022/11
8.	原著(症例報告除く)	Differential efficacy of TNF inhibitors with or without the immunoglobulin fragment crystallizable (Fc) portion in rheumatoid arthritis: the ANSWER cohort study 2022/07
9.	原著(症例報告除く)	The real-world effectiveness of anti-RANKL antibody denosumab on the clinical fracture prevention in patients with rheumatoid arthritis: The ANSWER cohort study 2022/07
10.	原著(症例報告除く)	Factors affecting drug retention of Janus kinase inhibitors in patients with rheumatoid arthritis: the ANSWER cohort study 2022/01
11.	症例報告	髄膜炎で発症し髄液中抗シトルリン化ペプチド抗体が臨床経過の推移と一致したリウマチ性髄膜炎の一例 2021/09
12.	原著(症例報告除く)	A Single-Center Retrospective Observational Study Evaluating the Favorable Predictive Factors for the Disease Control Time of Treatment with Tocilizumab in Patients of Rheumatoid Arthritis 2021/08
13.	原著(症例報告除く)	Comparison of efficacy between anti-IL-6 receptor antibody and other biological disease-modifying antirheumatic drugs in the patients with rheumatoid arthritis who have knee joint involvement: the ANSWER cohort, retrospective study 2021/07
14.	原著(症例報告除く)	Drug retention of sarilumab, baricitinib, and tofacitinib in patients with rheumatoid arthritis: the ANSWER cohort study 2021/07
15.	原著(症例報告除く)	The Association of Disease Activity and Estimated GFR in Patients With Rheumatoid Arthritis: Findings From the ANSWER Study 2021/05
16.	原著(症例報告除く)	Comparison of the drug retention and reasons for discontinuation of tumor necrosis factor inhibitors and interleukin-6 inhibitors in Japanese patients with elderly-onset rheumatoid arthritis-the ANSWER cohort study 2021/04
17.	原著(症例報告除く)	Mycophenolic acid, the active form of mycophenolate mofetil, interferes with IRF7 nuclear translocation and type I IFN production by plasmacytoid dendritic cells. 2020/11
18.	原著(症例報告除く)	Comparison of the efficacy and safety of biologic agents between elderly-onset and young-onset RA patients: the ANSWER cohort study 2020/07
19.	原著(症例報告除く)	Drug retention of 7 biologics and tofacitinib in biologics-naïve and biologics-switched patients with rheumatoid arthritis: the ANSWER cohort study 2020/06
20.	原著(症例報告除く)	Drug retention of secondary biologics or JAK inhibitors after tocilizumab or abatacept failure as first biologics in patients with rheumatoid arthritis -the ANSWER cohort study 2020/03
21.	原著(症例報告除く)	The family history of rheumatoid arthritis in anti-cyclic citrullinated peptide antibody-positive patient is not a predictor of poor clinical presentation and treatment response with modern classification criteria and treatment strategy: the ANSWER cohort study. 2019/10
22.	原著(症例報告除く)	Clinical Course of Amyloid A Amyloidosis Secondary to Rheumatoid Arthritis Treated with Anti-Rheumatic Drugs Including Biologic Agent: Case Series in Answer Cohort. 2019/08
23.	原著(症例報告除く)	Serum high-mobility group box 1 is correlated with interferon-α and may predict disease activity in patients with systemic lupus erythematosus. 2019/08
24.	その他	Correction to: Drug tolerability and reasons for discontinuation of seven biologics in 4466 treatment courses of rheumatoid arthritis-the ANSWER cohort study. 2019/05
25.	原著(症例報告除く)	Drug tolerability and reasons for discontinuation of seven biologics in elderly patients with rheumatoid arthritis -The ANSWER cohort study. 2019/05
26.	原著(症例報告除く)	Drug tolerability and reasons for discontinuation of seven biologics in 4466 treatment courses of rheumatoid arthritis-the ANSWER cohort study. 2019/04
27.	原著(症例報告除く)	Factors associated with the achievement of biological disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: the ANSWER cohort study. 2018/08
28.	原著(症例報告除く)	Drug retention and discontinuation reasons between seven biologics in patients with rheumatoid arthritis -The ANSWER cohort study. 2018/03
29.	原著(症例報告除く)	SLEの合併したATLの一例 2017/12
30.	その他	Comparison of Drug Tolerability and Discontinuation Reasons between 7 Biologics in Patients with Rheumatoid Arthritis -Results from Kansai Consortium for Well-Being of Rheumatic Disease Patients (ANSWER cohort)- 2017/10
31.	症例報告	Combined use of ursodeoxycholic acid and bosentan prevents liver toxicity caused by endothelin receptor antagonist bosentan monotherapy: two case reports 2014/07
32.	原著(症例報告除く)	Serum Interleukin 6 Before and After Therapy with Tocilizumab Is a Principal Biomarker in Patients with Rheumatoid Arthritis. 2013/07
33.	その他	Effective intravenous immunoglobulin therapy for Churge-Strauss syndrome (allergic granulomatous angiitis) complicated by neuropathy of the eighth cranial nerve: a case report. 2012/09
34.	その他	膠原病関連血管炎によるびまん性肺胞出血に対してairway pressure-release ventilationを補助療法として使用し著効を認めた3症例 2011/09
35.	原著(症例報告除く)	A case of rheumatoid pericarditis associated with a high IL-6 titer in the pericardial fluid and tocilizumab treatment. 2011/06
36.	原著(症例報告除く)	生物学的製剤導入に対する地域医療連携パス稼働下での生物学的製剤の選択および継続率 2011/06
37.	その他	Neutrophils Activate Plasmacytoid Dendritic Cells by Releasing Self-DNA-Peptide Complexes in Systemic Lupus Erythematosus. 2011/03
38.	その他	Inhibitor of IkappaB kinase activity, BAY 11-7082, interferes with interferon regulatory factor 7 nuclear translocation and type I interferon production by plasmacytoid dendritic cells. 2010/12
39.	その他	タクロリムスとミコフェノール酸モフェチルの併用療法が奏功した多剤抵抗性の全身性エリテマトーデスの一例 2010/09
40.	その他	Thymic stromal lymphopoietin plays an adjuvant role in BCG-mediated CD8(+) cytotoxic T cell responses through dendritic cell activation. 2010/08
41.	原著(症例報告除く)	長期休薬の後に発症したプロピルチオウラシル誘発性ANCA関連血管炎の一例 2010/06
42.	その他	Decrease of blood dendritic cells and increase of tissue-infiltrating dendritic cells are involved in the induction of Sjögren's syndrome but not in the maintenance. 2010/03
43.	その他	Statins, inhibitors of HMG-CoA reductase, function as inhibitors for cellular and molecular components involved in type I IFN production. 2010/03
44.	原著(症例報告除く)	Imidazoquinoline acts as immune adjuvant for functional alteration of thymic stromal lymphopoietin-mediated allergic T cell response. 2008/10
45.	原著(症例報告除く)	Hodgkin's reed-sternberg cell line (KM-H2) promotes a bidirectional differentiation of CD4+CD25+Foxp3+ T cells and CD4+ cytotoxic T lymphocytes from CD4+ naive T cells. 2007/09
5件表示
全件表示(45件)